** Shares of drugmaker Y-mAbs Therapeutics YMAB.O fall 8.5% to $4.75, hitting a near two-year low
** Company forecasts 2025 total revenue to be between $75 million and $90 million, below analysts' estimates of $104.54 million, according to data compiled by LSEG
** YMAB reports Q4 total revenue of $26.5 million, below analysts' estimates of $27.29 million
** In the past 12 months, YMAB has fallen 70%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。